Summary
CVS Health Corporation (CVS) announced on August 13, 2020, through an 8-K filing, the completion of a significant debt offering. The company entered into an Underwriting Agreement to issue and sell a total of $4,000,000,000 in aggregate principal amount of senior notes across three tranches: $1.5 billion in 1.300% Senior Notes due 2027, $1.25 billion in 1.750% Senior Notes due 2030, and $1.25 billion in 2.700% Senior Notes due 2040. These notes were offered under the company's existing shelf registration statement filed in May 2020. The net proceeds from this offering are estimated to be approximately $3,965,440,000 after deducting underwriting discounts and estimated expenses. This capital infusion is likely intended to strengthen the company's balance sheet, potentially fund ongoing operations, or support strategic initiatives, though the specific use of proceeds is not detailed in this filing.
Key Highlights
- 1CVS Health issued $4 billion in senior notes across three maturities: 2027, 2030, and 2040.
- 2The notes carry coupon rates of 1.300%, 1.750%, and 2.700% respectively.
- 3The offering was conducted under a previously filed Form S-3ASR registration statement.
- 4Net proceeds from the debt issuance are expected to be approximately $3.965 billion.
- 5The closing of the note sale was anticipated for August 21, 2020.
- 6Key underwriters included Barclays Capital Inc., BofA Securities, Inc., and Goldman Sachs & Co. LLC.